Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T22:24:10.553Z.
Calculation as of: 2026-10-06T22:24:10.553Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc4657557541446f84d9f7820ae4f915e84790dbce56ed6e08d87a0074ca8553
PEG RATIO
N/A
Viking Therapeutics, Inc.
Market Cap
$3.31B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | $3.31B | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
